Therefore, NKp30 represents a potential biomarker for refinement of patient stratification, and might identify AML patients with high risk of relapse among patients with intermediate prognosis, with potential improvement of therapeutic decision algorithms. Here, NCR3 is linked to acute myeloid leukemia.